| Cash Flow | 2025-09-30 |
|---|---|
| Net loss | -24,761,369 |
| Stock-based compensation expense | 8,320,419 |
| Deferred income tax expense | 1,056,960 |
| Inventory | 12,649,207 |
| Accounts payable | 9,523,062 |
| Accrued expenses | 4,093,124 |
| Due to related party | 8,924,965 |
| Net cash (used in) provided by operating activities | -5,492,046 |
| License payments | 5,750,000 |
| Net cash used in investing activities | -5,750,000 |
| Net proceeds from issuance of common stock | 15,166,842 |
| Net cash provided by financing activities | 15,166,842 |
| Net change in cash and cash equivalents | 3,924,796 |
| Cash and cash equivalents at beginning of period | 112 |
| Cash and cash equivalents at end of period | 3,924,908 |
CITIUS ONCOLOGY, INC. (CTOR)
CITIUS ONCOLOGY, INC. (CTOR)